Meeting Notice for 2025 Annual Shareholders' Meeting

2025 Annual Shareholders' Meeting (the "Meeting") of CHC Healthcare Group (the "Company") will be convened at 9:00 a.m., June 4, 2025, at No.88, Xing'ai Rd., Neihu Dist., Taipei City, Taiwan (The Company's conference room on the second floor). Registration time for shareholders to attend the Meeting will start at 8:30 a.m., and the location for registration will be the same as where the Meeting is.

1. The agenda for the Meeting is as follows:
   (1). Matters for Report
      A. 2024 business report
      B. Audit committee's report on review of 2024 audited financial reports
      C. To report the distribution of dividends and bonuses in cash of 2024
      D. To report the distribution of the compensations for employees and remunerations for directors of 2024
      E. To report the information of endorsements/guarantees in 2024
      F. To report the status of the private placement of common shares resolved by 2024 Annual Shareholders' Meeting
      G. To report the remunerations paid to directors in 2024
      H. Amendment to "Code of Ethical Conduct"
      I. To report the purpose and related matters of the 5th domestic issuance of unsecured convertible corporate bonds
   (2). Matters for Ratification
      A. 2024 business report and financial statements
      B. Proposal for 2024 earnings distribution
   (3). Matters for Discussion
      A. Amendment to "Articles of Incorporation"
      B. To release the non-competition restrictions on directors
      C. To propose the issuance plan for a private placement of common shares
   (4). Extemporary Motions

2. 2024 earnings distribution has been resolved by the Company's Board of Directors to distribute a cash dividend of NT$1.51 per share.

3. According to Article 172 of "Company Act", the essential contents shall be posted on the website of Market Observation Post System (https://mops.twse.com.tw).

4. The Company has proposed a private placement of common shares. Relevant information please refer to Attachment 1.

5. Shareholders who wish to attend the shareholders' meeting in person are requested to sign or stamp the "Attendance Card" and bring it to the venue for registration on the day of the Meeting. If an agent is entrusted to attend the Meeting, the shareholder shall sign or stamp the "Form of Proxy" and personally fill out the name and address of the agent, then deliver the form to CTBC Stock Affairs Agency Department, the stock affairs agency of the Company, at least five days before the day of the Meeting so that the attendance card can be sent to the agent accordingly.

6. If a proxy is solicited by any shareholders, the Company will compile and upload relevant information on the website of the Securities and Futures Institute (SFI) on May 2, 2025. Investors may refer to the "Free Database for Proxy Information" on SFI's website (https://free.sfi.org.tw) and input search criteria for relevant information.

7. Shareholders may cast electronic votes at the Meeting during which the electronic voting period will be from May 5, 2025 to June 1, 2025. Please login into the "eVoting Platform" on the website of Taiwan Depository & Clearing Corporation (https://stockservices.tdcc.com.tw) and cast votes in accordance with the instruction.

8. New shareholders who intend to submit the "Shareholder Specimen Chop" may download the form from the CTBC Trust Online Banking website, the Company's stock affairs agency.

9. The proxy tallying and verification service agent for the Meeting is the CTBC Stock Affairs Agency Department.

10. Please note and act accordingly.

Sincerely yours,

Board of Directors, CHC Healthcare Group

【Attachment 1】

Relevant information for the private placement of common shares proposed by the Company:

1. To enhance the relationship with strategic investors and consider the effectiveness of raising capital, the Company has proposed a private placement of common shares within the limit of 20,000 thousand shares and may be carried out in installments (no more than 3 times) within one year from the date resolved by the Meeting following Article 43-6 of "Securities and Exchange Act". Relevant information is as follows:
   (1). The basis for and reasonableness of pricing:
      A. The price per share set for privately placed common shares may not be lower than 80% of the reference price. The reference price shall be the higher of the following two calculations:
         (a). The simple average closing price of the common shares for either the 1, 3, or 5 business days before the price determination date, after adjustment for any distribution of stock dividends, cash dividends or capital reduction.
         (b). The simple average closing price of the common shares for the 30 business days before the price determination date, after adjustment for any distribution of stock dividends, cash dividends, or capital reduction.
      B. It is proposed to the Meeting to authorize the Board of Directors to determine the actual price determination date and issuance price in accordance with the status of selecting the specific persons and the market situation, also the price can't be lower than the percentage for the private placement pricing set by the Meeting.
      C. It is believed to be reasonable due to the basis for the method by which the price was set and terms above are all complied with relevant laws and regulations and in line with market situation.
   (2). The method, objectives, necessity and anticipated benefits for selecting the specific persons:
      A. The method and objectives for selecting the placees: To enhance the relationship with strategic investors, the Company plans to select the specific persons in accordance with Article 43-6 of "Securities and Exchange Act".
      B. The necessity and anticipated benefits: The Company proposed to engage with strategic investors through private placement to raise capital for the Company's long-term operating plan and future business development. It is expected that the private placement will strengthen future competitiveness, improve financial structure, enrich working capital and have advantage on the Company's long-term development. Cooperation with strategic investors may lead to broader business territory, which also has positive influence on shareholders' equity.

(3). The reasons for the necessity for conducting the private placement:

A. The reasons for not using a public offering: The regulation of a three-year non-trading period will help assure the long-term relationship between the strategic investors and the Company through private placement.

B. The limit on the private placement: Within the limit of 20,000 thousand shares

C. The use of the capital raised by installments and the anticipated benefits: The capital raised by installments through the private placement will be used to enrich working capital and for future development needs. It is expected to strengthen financial structure, replenish working capital and improve competitiveness of the Company.

(4). The Company has not experienced any significant change in managerial control due to the introduction of a strategic investor through private placement or other factors in the previous year.

2. The new private placement shares shall have the same rights and obligations as holders of common shares of the Company except for the transfer limitation of privately placed securities within three years of the delivery date stated in Article 43-8 of "Securities and Exchange Act". It is proposed to the Meeting to authorize the Board of Directors to apply to the competent authority for retroactive handling of public issuance procedures for the private placement shares after three full years since the delivery date based on "Securities and Exchange Act" and relevant rules.

3. It is proposed to the Meeting to authorize the Board of Directors to make amendment and supplement to the issuance price, terms and conditions, particulars of the plan and the actual status and other relevant matters related to the private placement if there occurs any update of R.O.C. laws or regulations, request by the authority, change of the market conditions or due to any subjective and objective factors.

4. It is proposed to the Meeting to authorize the Chairman to represent the Company to negotiate and sign any document and contract related to the private placement plan, also to handle the relevant issuance matters on behalf of the Company.

Based on Article 43-6 of "Security and Exchange Act", with regards to the required information of the Company's private placement proposal, please refer to the website of MOPS (https://mops.twse.com.tw): After accessing the website, investors may click on the "Thematic Area" section, then select "Investment Section," and proceed to the "Private Placement Section" to enter the search criteria. Relevant information is also available on the Company's website (https://www.chcg.com).